- Home
- LOCO vs SLN Comparison
LOCO vs SLN Comparison
Compare LOCO & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOCO
- SLN
- Stock Information
- Founded
- LOCO 1980
- SLN 1994
- Country
- LOCO United States
- SLN United Kingdom
- Employees
- LOCO N/A
- SLN N/A
- Industry
- LOCO Restaurants
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- LOCO Consumer Discretionary
- SLN Health Care
- Exchange
- LOCO Nasdaq
- SLN Nasdaq
- Market Cap
- LOCO 323.7M
- SLN 299.4M
- IPO Year
- LOCO 2014
- SLN N/A
- Fundamental
- Price
- LOCO $10.63
- SLN $4.81
- Analyst Decision
- LOCO Buy
- SLN Buy
- Analyst Count
- LOCO 2
- SLN 5
- Target Price
- LOCO $18.00
- SLN $32.60
- AVG Volume (30 Days)
- LOCO 168.4K
- SLN 60.5K
- Earning Date
- LOCO 07-31-2025
- SLN 08-07-2025
- Dividend Yield
- LOCO N/A
- SLN N/A
- EPS Growth
- LOCO N/A
- SLN N/A
- EPS
- LOCO 0.85
- SLN N/A
- Revenue
- LOCO $479,690,000.00
- SLN $27,169,000.00
- Revenue This Year
- LOCO $6.29
- SLN N/A
- Revenue Next Year
- LOCO $1.56
- SLN N/A
- P/E Ratio
- LOCO $12.61
- SLN N/A
- Revenue Growth
- LOCO 1.85
- SLN 22.28
- 52 Week Low
- LOCO $8.29
- SLN $1.97
- 52 Week High
- LOCO $14.10
- SLN $20.48
- Technical
- Relative Strength Index (RSI)
- LOCO 52.39
- SLN 34.88
- Support Level
- LOCO $10.40
- SLN $4.91
- Resistance Level
- LOCO $10.74
- SLN $5.34
- Average True Range (ATR)
- LOCO 0.26
- SLN 0.48
- MACD
- LOCO 0.04
- SLN -0.05
- Stochastic Oscillator
- LOCO 75.57
- SLN 0.71
About LOCO El Pollo Loco Holdings Inc.
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. Restaurant locations are typically free-standing and include drive-thrus, and menus include many low-priced options. Poultry is the company's largest food cost, accounting for roughly 38% of total food and paper cost, and the company manages that commodity price risk by using multiple suppliers and entering supply contracts of varying lengths depending on market conditions.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.